To investigate difference between Chinese pharmacopeia commission（ChP） and United States Pharmacopeia commission（USP） at enacting and revising plant medicines standards

and suggest reasonable proposals to revision of standards for Chinese medicine in China.By analyze the current situation of standards revision in USA and China

basic research of standards in "Chinese Pharmacopeia" should be improved;Focus on coordination and harmonization of series of varieties and wholeness of analysis methods;Difficulty of analysis consistency and chromatography normalization could be solved by applying control extract of botanicals or the control preparation;Pay high attention to the overall safety of drugs and choice of detection methods;We recommended to learn from USP

such as experience of drafting revised standards with low-cost

management model and philosophy of varieties of responsible person system.Found out insufficient in ChP by analyzing difference between ChP and USP

these advanced experience in USP should be mirrored and shifted to ChP

in order to provide a reference for development of our botanical drugs.